Critical Claim
Evidence Level
Confidence
Claim-Evidence Distance
Efficacy in disease model
In vivo (rodent)
High
Aligned
Durability of response
In vivo (rodent)
Moderate
Moderate gap
Safety and tolerability
In vivo (rodent)
Moderate
Moderate gap
Mechanism of action
In vitro
High
Aligned
Translatability to human
None
Low
Material gap
$125M+
Phase 1 clinical data (12–18 months)
Efficacy in humans
The proposed financing is sufficient to reach a key de-risking milestone, but only if scope is tightly controlled and translational efficacy remains.
Why I'd take the meeting
Compelling early data
Experienced team
Large unmet need
Clear development plan
Potential for platform expansion
What could stop me from investing
Uncertain human efficacy
Manufacturing scalability
Market size assumptions
Competitive landscape
Capital requirements
How do the preclinical data translate to humans?
What evidence supports the proposed mechanism?
What are the key manufacturing and scalability risks?
How was the target market size estimated?
What will the proceeds specifically be used for?